We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) , in partnership with Pfizer Inc. (PFE - Free Report) , announced that their diabetes pipeline candidate, ertugliflozin (MK-8835), has met the primary endpoint in a phase III study.
The double-blind, randomized, placebo-controlled study, VERTIS SITA2, showed that ertugliflozin (both 5 mg and 15 mg daily doses), when added to sitagliptin and metformin, led to A1C reduction in patients with type 2 diabetes. While the 5-mg dose reduced A1C by 0.69%, the 15 mg dose led to a 0.76% decline in A1C.
Ertugliflozin is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor.
The drug met the key secondary end-points of the trial as well.
Overall adverse event (AE) rates were also low in both the dosage arms of ertugliflozin compared to placebo.
These results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Munich, Germany.
Pfizer and Merck plan to submit an NDA in the U.S. for ertugliflozin and the two fixed-dose combination tablets, ertugliflozin/Januvia and ertugliflozin/metformin, by 2016 end.
Merck has several late-stage candidates in its pipeline targeting multiple disease areas such as atherosclerosis, cancer, diabetes and cardiovascular diseases. The company has more than 10 candidates in phase III development. Some of the important candidates include MK-0859 (anacetrapib – cholesterol management – phase III), verubecestat (Alzheimer’s disease – phase III) and Zinplava (bezlotoxumab).
Both Merck and Pfizer currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in health care sector are ANI Pharmaceuticals (ANIP - Free Report) and Johnson & Johnson (JNJ - Free Report) . While ANI Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
MERCK & CO INC Price
MERCK & CO INC Price | MERCK & CO INC Quote
Both Merck and Pfizer currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in health care sector are ANI Pharmaceuticals (ANIP - Free Report) and Johnson & Johnson (JNJ - Free Report) . While ANI Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>